Experimental evidence suggests that a combination of vasopressors and an alpha blocking agent or beta stimulating agent may prove clinically useful in the treatment of cardiogenic shock.
Such therapy would, in effect, combine what until now have been two conflicting schools of thought about the use of vasoactive drugs to counteract shock following coronary occlusion, Herbert Gold, MD, told the annual meeting in Chicago of the American College of Cardiology.
On the one hand are those who favor use of alpha and beta adrenergic stimulators, and on the other are the physicians who prefer an alpha adrenergic blocking agent as the drug of choice.
"Our experiments have led us to believe that a combination of these two schools of thought might provide more beneficial effects for the treatment of cardiogenic shock," Dr. Gold said.
Working with dogs in which cardiogenic shock was experimentally induced, Dr. Gold, Eliot Corday, MD, and